All News

More evidence to support role of Tyk2 in management of skin psoriasis. Dr.April Armstrong #RNL2024 @RheumNow https://t.co/9vuuhJMj36

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Nice summary of data as to why IL-17 or IL-23 are generally favoured by dermatology for psoriasis @_AprilArmstrong @RheumNow #RNL2024 https://t.co/qfAn2AHilX

Links:

Richard Conway RichardPAConway ( View Tweet)
Dr. A. Armstrong's Key Takeaways for PsO. TNFi - great in PsA and pregnancy IL-17i - robust PsO efficacy and in PsA IL-23i - robust in PsO, fewer injections, and efficacious in PsA. #RNL2024 @RheumNow @_AprilArmstrong https://t.co/j8LaOGITuf

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Did you know of all the small oral molecules, #apremilast is the only one approved for all stages of #psoriasis (mild to severe)? - Dr. Armstrong polls the audience on their thoughts then revealing the correct answer #RNL2024 @rheumnow https://t.co/NXSiaaGp3p

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Dr. A. Armstrong shares dermatology/dermatologist trends in PsO. 1. They tend to shorted then interval between injections as opposed to the amount of medication per dose. 2. Derms generally wait 6 months to switch meds 3. Like rheums, derms tend to switch classes (of tx agent)… https://t.co/HWbJMwnwkE https://t.co/bgKw7ynANN

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Dr. A. Armstrong shares dermatology/dermatologist trends in PsO. 1. They tend to shorted then interval between injections as opposed to the amount of medication per dose. 2. Derms generally wait 6 months to switch meds 3. Like rheums, derms tend to switch classes (of tx agent)… https://t.co/HWbJMwnwkE https://t.co/bgKw7ynANN

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
When it comes to skin, this is how derms think and there is data to support this. - Dr. Amstrong on how IL-17i and IL23i are preferred over TNFi #psoriasis #RNL2024 @rheumnow https://t.co/UZWNgOljRh

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Dermatologic approach to choosing treatment in psoriatic disease. The presence of psoriatic arthritis is an initial branch point and why co-management is so crucial in these patients @_AprilArmstrong @RheumNow #RNL2024 https://t.co/m26WiEUmPI

Links:

Richard Conway RichardPAConway ( View Tweet)
#RNL2024 @RheumNow @_AprilArmstrong Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs - Fast onset - High efficacy with 2/3 PASI 100 by wk 16 (BE READY) https://t.co/cKh7j4KBs9

Links:

Eric Dein ericdeinmd ( View Tweet)
How/when to choose biologics in pts with active psoriasis from Dr April Armstrong #rnl2024

Dr. John Cush RheumNow ( View Tweet)

#RNL2024 @RheumNow TREAT-EARLIER - MTX for Clinically Suspect Arthralgias No overall diff vs PBO High risk pts had benefit, but not sustained at 2 yrs But sustained reduction in HAQ & MRI inflammation - Signs for hope? Overall, prevention studies have been disappointing https://t.co/DtBlGaw0Lf

Links:

Eric Dein ericdeinmd ( View Tweet)
antibody (Keep)

Anti-Drug Antibodies and Biologic Drug Responses

d Jack Cush, MD

A prospective cohort study suggests the presence of antidrug antibodies may be associated with bDMARDs nonresponse in rheumatoid arthritis (RA). Should we be monitoring ADAbs (especially in nonresponders)?

Read Article
human figures on blue circle

New therapeutic approach for the treatment of sarcoidosis

d Eureka Alert!

A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis. In a clinical study, the inhibition of a specific signaling pathway showed clear success in the treatment of granulomas in the skin. This opens up new therapeutic paths for sarcoidosis and similar inflammatory diseases. The results were recently published in the journal Lancet Rheumatology.

Read Article
2023

2023 Rheumatology Year in Review

d Jack Cush, MD

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  



2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  

Read Article
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/S7MaAz6fX2 https://t.co/5ETcQRz8Fd

Links:

Dr. John Cush RheumNow ( View Tweet)
pso.PsA_.NPF_.jpg

Best of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?

d Jack Cush, MD

Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

Read Article
RheumNow Podcast square

CBT or Naltrexone in Fibromyalgia (12.8.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  Be sure to catch the early registration break for 2024 RheumNow Live.

Read Article
#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz
Md Yuzaiful Md Yusof  ( View Tweet)
Rashes in Rheumatology at #ACR23 Name the rash? @Rheumnow https://t.co/7CNqOESctW

Links:

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
pregnant, pregnancy, mother, fertility

Pregnancy Updates That Will Change The Way I Practice

d Rachel Tate, DO

ACR Convergence is truly drinking from the proverbial fire hose. It’s a beautiful mash-up of basic science and treatment updates meets guidelines, recommendations, and disease identification.

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.